The clinical AI platform for longevity medicine in Spanish, proven daily in the founder's own practice.
Dr. Miguel Bravo, Founder. Plastic surgeon and longevity physician, licensed in Spain and Abu Dhabi.
Navigate with the arrow keys, the dots, or the arrows below
Thousands of clinics want to sell longevity care in Spanish, and the engine to power them does not exist.
US tools are English-only and break on EU units. The combination lane is wide open.
B2B is the venture market: clinics across Spain and 20 LatAm countries. The UAE practice is the proof and the cash.
A few hundred clinics at 59-169 EUR/mo is tens of millions EUR in ARR. Every figure is our own projection.
Incumbents validate demand on both sides, and nothing Spanish-native exists on the platform side.
The only comparable platform is NGM. Our edge: the engine, the B2B shape, the channel.
The data, the channel, and the content that win this market are still unowned.
The longevity wave, GLP-1, and AI maturity are compounding now. Every quarter compounds.
The founder's practice funds the proof before investors do, so the platform raises from strength.
Modern Age then NGM is the template. Practice first, then platform.
Two engines run from day one: a cash-pay UAE practice and a Spanish-native B2B platform, both asset-light.
No clinic, no machines, no capex. The cost structure of a software company.
Our engine reads any country's labs and reasons like a 15-specialist panel.
Running in his practice today. Not a deck, a working product.
Optimization Scorecard
Optimal ranges, not normal ones.
15 lenses, one voice
Specialists internal, one synthesis.
Evidence-tiered guidance
Graded; never prescribes.
Red-flag safety net
Physician findings escalated.
Trajectory mode
Panels over time, patient's units.
Branded, editable output
The physician edits and signs.
We win on owned depth, data, authority, and distribution, not on a regulatory quirk.
Every stage is profitable and funds the next, so we never bet the company.
Practice + design partners
UAE practice live, 6-10 clinics on free Preop.
Paid B2B launch
Paid tiers open in Spain; the practice scales.
Raise from strength
Outside capital only after the metrics gate.
LatAm scale
LatAm, white-label, CE mark: rails already built.
You never bet the company. Each step is profitable and buys the next.
We raise only after the metrics prove cash, conversion, retention, and data.
The Stage 3 raise happens from strength.
Contribution positive
The UAE practice covers its base.
Free converts to paid
Half the design partners convert.
Usage holds
Reports per clinic hold.
Dataset grows
A de-identified dataset compounds.
One asset, two revenue lines, already running: the founder's practice and the Spanish-native platform.
The US comps own every patient they serve. Longeva scales twice.
A surgeon-founder opens the first clinics through peri-operative care, a channel rivals cannot reach.
Land with Longeva Preop, expand to longevity. The founder's practice is the living demo.
The founder built the engine, owns the brand, treats the patients, and has the network.
Board-certified plastic surgeon (FEBOPRAS), colegiado in Spain and DOH-licensed in Abu Dhabi. Breakeven needs only ~10-15 batched physician-hours a month. Open seat: a full-time operator co-founder.
Five owned, compounding assets defend this business, and not one is a law.
Clinical authority
A surgeon-founder running the engine on his patients.
Distribution
The warm SECPRE channel and a Spanish corpus.
Switching costs
Clinics embed it; each patient's trajectory lives in it.
The engine, honestly
A real head start; the durable edge is Spanish-native depth.
The data, honestly
A research asset today, a moat at scale.
Longeva wins in every regulatory scenario, including the ones that hurt rivals.
Regulation is a filter we pass, not a wall we hide behind.
Status quo
The rules stay; we execute the staircase. No law change needed.
Clinic + telehealth rules tighten
Compliance-native in Spain, DOH-licensed in the UAE. Tightening removes grey-zone rivals.
AI + device enforcement tightens
MDR-prudent from day one; CE marking budgeted at scale. A barrier newcomers cannot afford.
Premium cash pricing in the UAE, recurring software pricing in Spanish: two revenue lines from day one.
All prices are estimates, to be confirmed in the 90-day validation.
A structured round, first close 150k EUR, hard cap 300k EUR, to productize the platform, launch the UAE practice, and hit the metrics that unlock the seed.
On a post-money SAFE, cap set with the lead. No invented traction.
A 90-day, low-cost validation gates all larger spend.
First paying evaluations, 3 signed design partners, the benchmark. Capital follows proof, never precedes it.